Back to top

Image: Bigstock

Here's Why Investors Should Buy Integra LifeSciences Now

Read MoreHide Full Article

Integra LifeSciences Holdings Corporation (IART - Free Report)  develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of burns and skin defects, spinal and cranial disorders, orthopedics and other surgical applications. The company has rallied 19% over the last six months, better than the S&P 500’s 8.8% gain and broader industry's 10.1%. The stock has a market cap of $3.83 billion.The company’s five-year historical growth rate is also favorable at 3.7% as compared to 2.8% of the S&P 500 index.

With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick at present. Let’s find out whether the recent positive trend is a sustainable one.

Integra LifeSciences has a positive earnings surprise of 0.8% for the last four quarters. Also, it has a long-term expected earnings growth rate of 10.8%.



The market is upbeat about Integra LifeSciences’ latest developments, the most recent one being the launch of collagen matrices — Revize/Revize-X — for plastic and reconstructive surgery, expanding its tissue technology portfolio.

Also, following the CE Mark approval,Integra LifeSciences recently announced the launch of meshed acellular dermal tissue matrix (ADM) — SurgiMend PRS Meshed — for both pre- and sub-pectoral breast reconstruction in Europe.

Moreover, Integra LifeSciences has finally completed the Codman Neurosurgery business acquisition from Johnson & Johnson, expanding its neurosurgery business.

These latest developments indicate that the company has the capability to sustain the momentum.

Other Key Picks

Other top-ranked stocks in the medical sector are Abbott (ABT - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Thermo Fisher Scientific Inc. (TMO - Free Report) . Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Abbott has a long-term expected earnings growth rate of 10.7%. The stock rallied roughly 34.6% over the last year.

IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock gained 43.4% last year.

Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock gained 27.6% last year.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.

See these buy recommendations now >>

Published in